What is the recommended dose of letrozole for treating adenomyosis?

Letrozole Dosing for Adenomyosis

The recommended dose of letrozole for treating adenomyosis is 2.5 mg, administered either daily or three times weekly, for a duration of 3 months. This dosing has been shown to effectively reduce dysmenorrhea, menorrhagia, and adenomyoma volume in symptomatic women.

Evidence-Based Dosing Regimens

The available research demonstrates two effective dosing strategies for letrozole in adenomyosis:

Daily Dosing Protocol

• 2.5 mg once daily for 12 weeks was shown to reduce adenomyoma volume by 40.9% and improve symptoms comparably to GnRH agonists 1
• This regimen achieved significant reductions in both uterine size and adenomyoma volume without significant differences compared to goserelin 3.6 mg monthly 1

Intermittent Dosing Protocol

• 2.5 mg three times weekly for 3 months demonstrated marked improvement in dysmenorrhea (VAS scores, P = 0.0001) and menorrhagia (PBAC scores, P = 0.0001) 2
• This lower-frequency regimen allowed women to maintain regular menstrual cycles while achieving symptom relief 2
• Hemoglobin concentrations improved significantly (P = 0.0001) with this dosing schedule 2

Clinical Outcomes and Comparative Effectiveness

Both letrozole dosing regimens achieve comparable efficacy to GnRH agonists while offering distinct advantages:

• Sonographic improvements occur with both protocols, including reduction in diffuse adenomyosis of the myometrium (P = 0.015) and junctional zone (P = 0.025) 2
• Women with adenomyoma respond well to letrozole therapy (P = 0.049), with particularly strong responses in focal adenomyosis involving the outer myometrium (P < 0.001) 2
• Letrozole is significantly more cost-effective than GnRH agonist treatment while producing no noticeable side effects 2

Treatment Duration and Special Considerations

The standard treatment duration is 3 months (12 weeks), which has been validated in multiple studies 2, 1:

• Symptom improvement is progressive, with continued benefit throughout the 12-week treatment period 2
• Unlike GnRH agonists that cause amenorrhea, letrozole allows regular menstruation, which may be preferable for some patients 2

For Women Undergoing IVF

For adenomyosis patients awaiting assisted reproductive technology, letrozole 2.5 mg should be considered, particularly when:

• Long-term GnRH agonist treatment (≥3 months) has failed to adequately suppress estrogen production 3
• Severe adenomyosis is present, as GnRH agonist monotherapy may be insufficient to suppress local estrogen production from adenomyotic lesions 3
• A 21-day course of aromatase inhibitor can reduce hyperestrogenism and improve clinical outcomes in patients with previous embryo transfer failures 3

Important Clinical Caveats

Monitor estradiol levels in severe adenomyosis cases: Women with severe adenomyosis may present with hyperestrogenism due to local production from lesions even after long-term GnRH agonist treatment 3. Testing estradiol concentrations is mandatory in these patients to guide therapy selection 3.

Fertility considerations: Two pregnancies occurred during letrozole treatment in one study, indicating that contraception should be discussed if pregnancy is not desired 1. However, for women seeking fertility preservation, letrozole represents a viable uterine-sparing option 2, 1.

Note on FDA approval: While letrozole is FDA-approved at 2.5 mg daily for breast cancer treatment 4, its use in adenomyosis represents off-label prescribing based on research evidence demonstrating efficacy and safety in this population 2, 1, 5.